Drugs targeting DNA repair mechanisms inside cells are showing real promise for a range of tumors and AstraZeneca believes it is well ahead of rivals in the emerging cancer field.
Chief Executive Pascal Soriot said on Friday that while DNA damage response (DDR) was under-recognized by investors, oncologists were already "very excited" by its potential.
Work on how cells repair damaged DNA landed Swedish, U.S. and Turkish scientists the Nobel Prize for Chemistry last year and AstraZeneca's recently approved Lynparza is an early example of a drug that builds on this new understanding.
Chief Executive Pascal Soriot said on Friday that while DNA damage response (DDR) was under-recognized by investors, oncologists were already "very excited" by its potential.
Work on how cells repair damaged DNA landed Swedish, U.S. and Turkish scientists the Nobel Prize for Chemistry last year and AstraZeneca's recently approved Lynparza is an early example of a drug that builds on this new understanding.
